Introduction
Pulmonary arterial hypertension (PAH) is a fatal and progressive condition characterized by the presence of precapillary pulmonary hypertension at right heart catheterization (mean pulmonary arterial pressure ⩾25 mmHg at rest and wedge pressure ⩽15 mmHg) and high pulmonary vascular resistance (>3 Wood units) in the absence of other causes of precapillary pulmonary hypertension, like lung disease or chronic thromboembolic pulmonary hypertension. 1 PAH is the first group of the pulmonary hypertension classification 1 (Table 1 ). In the idiopathic form, no etiology is found. In the heritable form there is a context of familial history or a genetic mutation. Other forms are associated with drugs and toxins, connective tissue diseases, liver disease, human immunodeficiency virus (HIV), congnital heart disease or schistosomiasis. Remodeling of the pulmonary vasculature is responsible for an increase in pulmonary vascular resistance leading to progressive right heart failure and ultimately death. It is partially explained by an imbalance between three main pathways, the prostacyclin, the nitric oxide and the endothelin pathways. 4 Current treatments aim to reestablish the balance between the vasoactive and vasodilatory capacities in the lung vasculature.
Endothelin and the pulmonary circulation
Increased levels of endothelin (ET)-1 have been observed in the plasma and pulmonary vascular endothelium of patients with pulmonary hypertension and increased plasma levels were also observed in experimental animal models of PAH. [5] [6] [7] ET-1 is the principal isoform in the cardiovascular system, 8 and it is one of the most potent vasoconstrictors. The activity of ET-1 is mediated through two distinct receptors: ET A and ET B . 9, 10 In physiological conditions vasoconstriction is essentially mediated by ET A receptors which predominate on vascular smooth muscle cells (SMCs). ET B receptors are mainly expressed on the vascular endothelium and mediate vasodilation. This is the reason why theoretically it was thought that selective ET A inhibition may be more efficient. However, in pathological conditions like PAH, ET B receptors are upregulated on SMCs and downregulated on endothelial cells, [11] [12] [13] suggesting that dual endothelin receptor antagonism (ERA) may be better than ET A -selective inhibition. 14 There is however no clinical evidence of improved efficacy of one or the other type of ERA.
The dual ERA bosentan was approved as the first oral therapy for PAH, based on two randomized controlled trials (RCTs) showing improvements in exercise capacity, 15, 16 hemodynamic parameters 15 and time to clinical worsening. 16 However, the treatment was associated with an increased, dosedependent, incidence of elevated liver transaminases, and an increase in plasma bile salts and alkaline phosphatases 17 attributed to inhibition of the bile salt export pump by bosentan and its metabolites. 18 Peripheral edema was also observed with bosentan. 16 An extensive drug discovery program was then started to maximize the inhibition of the ET receptors and minimize the risk of elevated liver enzymes and fluid retention. 19 
Macitentan pharmacology
Macitentan is the result of this optimization program. It is a dual ERA with enhanced tissue penetration (related to greater lipophilicity) and receptor binding properties, and superior efficacy in animal models. [19] [20] [21] The structure of macitentan is derived from the structure of bosentan. Macitentan does not inhibit bile salt transport. 23 Macitentan also shows a favorable drug-drug interaction profile. 24 Concomitant use of rifampicin, which reduces macitentan exposure, should be avoided. 25
Macitentan: clinical evidence
The effects of macitentan have been extensively investigated in 15 phase I studies in more than 300 subjects, 14 a phase II study (in patients with idiopathic pulmonary fibrosis) 26 and the pivotal phase III study with an ERA in PAH to improve clinical outcome (SERAPHIN trial 27 ). Specific efficacy aspects have been detailed in many more publications (effect on hospitalizations, 28 on prevalent and incident patients, 29 on hemodynamic parameters, 30 on health-related quality of life, 31 and on the relationships between the 6 minute walking distance (6MWD) and long-term outcomes, 32 between morbidity and mortality, 33 and between pharmacokinetics and hemodynamic efficacy 34 ). New studies have also been dedicated to different pulmonary hypertension (PH) groups (inoperable chronic thromboembolic pulmonary hypertension 35 and pulmonary hypertension due to left ventricular dysfunction 36 ), to exploratory end-points (Table 2) , and to real-life experience ( Table 2 ).
The SERAPHIN trial evaluated the efficacy and safety of two doses of macitentan (3 and 10 mg once a day) by using a composite primary endpoint of time to first morbidity and (all-cause) mortality event in 742 patients with symptomatic PAH in a randomized, double-blind, multicenter, placebo-controlled, event-driven trial. After randomization, 250 patients received placebo, 250 received macitentan 3 mg and 242 received macitentan 10 mg.
Eligible patients were aged ⩾12 years with confirmed PAH diagnosis (idiopathic or heritable PAH, PAH associated with connective tissue disease, repaired congenital systemic-to-pulmonary shunts, HIV infection, drug use or toxin exposure). 
Morbidity and mortality
Macitentan 3 and 10 mg daily was effective in delaying the disease progression, reducing the risk of a morbidity or mortality event by 45% (10 mg) and by 30% (3 mg) over the treatment time as compared with placebo. 27 Macitentan treatment also significantly reduced the composite secondary endpoint of death due to PAH or hospitalization for PAH by 50% (10 mg versus placebo, p < 0.001). The risk of hospitalization for PAH in the group treated with 10 mg of macitentan was reduced by 51.6% compared with the placebo group (p < 0.0001), the rate of hospitalization for PAH by 49.8% (p < 0.0001), and the number of hospital days by 52.3% (p = 0.0003). 28 The incidence of all-cause death and death due to PAH did not differ significantly between the macitentan and placebo group. However, as PAH is a progressive disease, clinical deterioration is likely to precede death which is rarely the first recorded event. 27 To overcome the hurdle of evaluating survival benefits in rare diseases the use of real-world observational data has been proposed to complement RCT data. To this end, a prediction model based on the US REVEAL registry data has been used to further explore the effect of macitentan on mortality. This analysis suggested that, over 3 years, the risk of mortality with macitentan 10 mg was 31% lower than that predicted from the model (p = 0.033). 37 It is noteworthy that the patients enrolled in the SERAPHIN trial were younger than currently observed in the western countries; the mean age of PAH patients at diagnosis averaging 50 ±14 and 65 ±15 years in recent registries (French, COMPERA and US REVEAL registries). 38 The Therefore, the real-world effects of macitentan on morbi-mortality may be different from a clinical trial.
The strengths of the SERAPHIN trial are the large number of included patients and the prolonged observation time of the trial. It is also the first study in PAH powered for a robust clinical endpoint (morbidity and mortality) instead of a change in 6MWD.
Functional class and exercise capacity
The WHO FC at 6 months improved in a higher percentage of patients receiving 10 mg of macitentan (p = 0.006), and the treatment effect on the 6MWD with 10 mg dose versus placebo was 22.0 m [97.5% confidence interval (CI), 3.2-40.8; p = 0.008].
Interestingly, a post hoc analysis of the SERAPHIN trial showed that patients with higher absolute values of the 6MWD at baseline or at month 6 had better prognosis but that the magnitude of change in 6MWD was not associated with longterm clinical outcomes. 33 This confirms that establishing absolute thresholds of 6MWD as treatment goals in daily clinical practice make sense. 39 Similarly a meta-analysis of 22 shortterm RCTs in PAH (including 3112 patients), showed that improvements in the 6MWD did not reflect the benefit in clinical outcomes, such as death, hospitalization for PAH and initiation of PAH rescue therapy. 40 Furthermore, the MAESTRO study conducted in patients with PAH associated with Eisenmenger syndrome, did not reach its primary endpoint of change in 6MWD from baseline to week 16 of treatment, 41 while macitentan reduced the exploratory endpoint N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in the global cohort and improved pulmonary vascular resistance index and exercise capacity in the hemodynamic substudy. The results of this RCT are difficult to interpret as there was an unexpected improvement in the placebo arm, which had not been observed in a previous study conducted with bosentan, 42 and significantly contribute to the failure to achieve the primary endpoint in the MAESTRO trial. Of note, this study, as opposed to the bosentan study in Eisenmenger patients, included a significant proportion of patients with Down's syndrome and patients with complex cardiac defects. The longterm open-label trial in Eisenmenger patients (MAESTRO-OL; ClinicalTrials.gov identifier: NCT01739400) is also completed but results are not yet available (Table 2) .
Hemodynamics
A subset of 187 patients in the SERAPHIN trial (68 randomized to placebo, 62 to macitentan 3 mg and 57 to macitentan 10 mg) underwent right heart catheterization at baseline and after 6 months (n = 147) of treatment. 27, 30 Cardiopulmonary hemodynamic parameters and NT-proBNP were assessed. The baseline characteristics of the patients in the hemodynamic substudy were similar to the total SERAPHIN population and balanced between the different treatment groups. Both doses of macitentan significantly reduced pulmonary vascular resistance (PVR) and increased cardiac index, as compared with the placebo group. 27 Absolute levels of cardiac index, right atrial pressure (RAP), and NT-proBNP at baseline and after 6 months of treatment, but not their changes, were associated with morbidity or mortality events. Lower risk for morbidity or mortality was observed in patients with cardiac index > 2.5 l/min/m 2 , RAP < 8 mmHg, or NT-proBNP < 750 fmol/ml after 6 months of treatment [hazard ratio (HR) 0. The mechanism of action by which macitentan influences hemodynamic parameters will be studied in the ongoing REPAIR (right ventricular remodeling in pulmonary arterial hypertension) trial evaluating the effects of macitentan on right ventricle remodeling in PAH assessed by cardiac magnetic resonance imaging (ClinicalTrials.gov Identifier: NCT02310672) ( Table 2) .
Quality of life
Macitentan (10 mg) improved seven to eight domains of the short form health survey (SF-36) questionnaire assessing health-related quality of life (HRQoL) 31 and reduced significantly the risk of a three-point or greater deterioration in physical component summary score (HR 0.60; 95% CI, 0.47-0.76; p < 0.0001) and mental component summary score (HR 0.76; 95% CI, 0.61-0.95; p = 0.0173) until end of treatment. Patients with a HRQoL at baseline greater than the median baseline value had improved long-term outcomes. Potential limitation of these analyses is that the SF-36 questionnaire is a generic measure tool of HRQoL and is not created to specifically assess quality of life in PAH patients. Also, the longterm effect is difficult to evaluate due to missing data: at 6 months HRQoL was not available for 134 (18.9%) of patients and imputation for missing data was used. At 12 months 30% of data were missing making it impossible to analyze.
Of note, a disease-specific patient-reported outcome (PRO) instrument, the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT ® ) questionnaire, has been recently finalized and validated using data from the SYMPHONY trial which included 278 US patients with PAH treated with macitentan. 43 Tolerability and safety Macitentan was generally well tolerated in the SERAPHIN study. Similar rates of adverse events were reported in the three study arms: 96% in patients treated with macitentan 3 mg daily, 94.6% in patients treated with macitentan 10 mg daily and 96.4% in patients from the placebo group. Serious adverse events were similarly reported in the three groups: 52% with macitentan 3 mg daily, 45% with macitentan 10 mg daily and 55% with placebo. 27 There was no difference in incidence of edema, a well-known adverse event of ERAs, between the placebo and the macitentan arms (18.1% versus 18.2%). 27 Treatment with ERAs, especially with bosentan, has been associated with increased levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) due to inhibition of the bile salt transport. 17 In the SERAPHIN trial, 3.4% of patients with macitentan compared with 4.5% of patients in the placebo group developed ALT or AST levels >3 times the upper limit of normal (ULN) and bilirubin levels >2 times the ULN. 27 Severe anemia (hemoglobin ⩽ 8 g/dl) was observed more frequently in the macitentan group (10 mg) compared with the placebo group (4.3% versus 0.4%).
Anemia, nasopharyngitis, bronchitis and headache were reported more frequently (delta>3%) in the group treated with macitentan 10 mg compared with the placebo group. 27 Of note, the SERAPHIN trial was underpowered for the identification of rare severe side effects.
Although the trough plasma concentration of macitentan and its active metabolite was about twofold higher in PAH patients from the SERAPHIN trial than in healthy people, this did not translate to a significant difference in exposure expressed as maximum plasma concentration (Cmax) or area under the plasma concentration-time curve (AUC) over a dosing interval. 44 
Dosage and (contra) indications
Macitentan (10 mg once daily orally) was approved in 2013 by the United States Food and Drug Administration (US FDA) and European Medicines Agency for the treatment of PAH to delay disease progression and to reduce hospitalizations (US, https://opsumit.com/opsumit-pre scribing-information.pdf) and for the long-term treatment of adults with PAH functioning in New York Heart Association class II-III (Europe, https://www.actelion.com/documents/en -rebranded/our-products/opsumit-smpc.pdf), in monotherapy or in combination therapy.
Teratogenicity is a well-known side effect shared by all ERAs. Macitentan is therefore contraindicated in pregnant women (US and Europe). In Europe its use is also contraindicated in breastfeeding women and in women of childbearing potential who are not using reliable contraception (however reliable contraception is recommended in all women of childbearing potential with PAH because of the negative prognosis of pregnancy). However, since the SERAPHIN trial included a large number of patients already treated with PAH therapy (mostly PDE5 inhibitors) and since patients with and without background therapy were prespecified subgroups for analysis, combination therapy has been evaluated (although this was not the primary endpoint of the trial) in a post hoc analysis. 45 The risk of morbidity/mortality was reduced by 38% in patients on macitentan and background therapy compared with those on background therapy alone. Also, the risk of being hospitalized for PAH was reduced by 37.4% compared with patients receiving background therapy alone. Macitentan treatment in combination with background therapy was associated with improvements in exercise capacity, functional class, cardiopulmonary hemodynamics and HRQoL compared with background therapy alone.
Clinical experience with macitentan
Since the publication of the AMBITION trial (initial use of ambrisentan plus tadalafil in PAH 46 ), which showed a significantly lower risk of clinical failure (p < 0.01) in patients receiving initial bi-therapy with ambrisentan and tadalafil compared with patients treated with ambrisentan or tadalafil in monotherapy, there is a growing interest for initial combination therapy. Actually, it is not known if these results can be extended to other drugs from the same classes. Used in combination, there is clear pharmacokinetic distinction between the three ERAs. In healthy volunteers the concomitant administration of bosentan and sildenafil showed a decrease in the AUC of sildenafil by 62.6% and an increase in the AUC of bosentan by 49.8%. 47 The concomitant administration of bosentan and tadalafil decreased the AUC of tadalafil with 41.5% and slightly increased the AUC of bosentan by <20%. 48 There were no significant interactions between ambrisentan and sildenafil, 49 ambrisentan and tadalafil, 50 and macitentan and sildenafil 51 in healthy volunteers.
A small trial evaluating the effects of first-line oral combination therapy of macitentan and tadalafil in patients with newly diagnosed PAH is currently recruiting (OPTIMA; ClinicalTrials.gov Identifier: NCT02968901, Table 2 ), and will give better insights in the place of macitentan in PAH treatment.
Moreover, as combination dual therapy strategies are becoming more and more standard of care, the question of initial triple therapy led to the initiation of the TRITON trial evaluating initial triple (tadalafil, macitentan and selexipag) versus dual oral therapy (tadalafil, macitentan and placebo) (ClinicalTrials.gov Identifier: NCT02558231).
Macitentan in daily practice: the postmarketing experience
Although there was no difference in incidence of elevated hepatic transaminases between the placebo and the macitentan arms in the SERAPHIN trial, 27 a first case of fulminant liver failure, with a probable autoimmune origin, was recently reported in a patient treated with macitentan, 52 prompting a modification to the US-approved labeling for macitentan. The European label was unchanged but already mentioned that liver enzymes should be measured before starting treatment by macitentan and monthly monitoring of AST and ALT was recommended. If sustained, unexplained clinically relevant increases in aminotransferases occurred or if these elevations are accompanied with a more than two-fold ULN values of bilirubin or with a clinical symptoms of liver injury, macitentan should be discontinued. Once transaminase levels had normalized, reintroduction of macitentan could be considered in patients without clinical symptoms of liver injury (https://www.actelion.com/documents/en -rebranded/our-products/opsumit-smpc.pdf). The US FDA also mandated a long-term surveillance program, the OPUS registry (ClinicalTrials. gov Identifier: NCT02126943), which was initiated in 2014 to characterize the safety profile of macitentan and to describe clinical characteristics and outcomes of 5000 patients treated with macitentan in a real-world, post-marketing setting.
In the context of ERA hepatotoxicity, great caution has been applied to their use in patients with portopulmonary hypertension due to end-stage liver disease. However, small case series reported favorable results with bosentan and ambrisentan. 53, 54 The PORtopulmonary Hypertension Treatment wIth macitentan, a randOmized clinical trial (PORTICO study; ClinicalTrials.gov Identifier: NCT02382016) that was presented at the 2018 ERS annual meeting, included 84 patients with mild-to-moderate hepatic impairment and showed a significant improvement in the primary endpoint of PVR without safety issues. 55 As ERA therapy can cause anemia (also reported for macitentan), hemoglobin levels should be measured before starting treatment and macitentan should not be administrated in patients with severe anemia (https://www.actelion.com/docu ments/en-rebranded/our-products/opsumit-smpc .pdf). Hemoglobin measurements should be repeated during treatment as clinically indicated.
Drug interactions occur with strong CYP3A4-inducers or inhibitors resulting in reduced (CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin) or increased (CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir) plasma concentrations of macitentan. However, macitentan seems to have less drug interactions compared with other ERAs 24 but this should be confirmed in larger populations in clinical practice.
Perspectives
Macitentan has been the first drug demonstrating an effect on long-term outcome in PAH in addition to improvements in functional class and exercise capacity. Multiple publications (from basic science to RCT) have illustrated and enforced the evidence on efficacy and safety of this drug. Some uncertainties still exist regarding the effects in children (TOMORROW study; ClinicalTrials.gov Identifier: NCT02932410), and the long-term effects in Eisenmenger patients (MAESTRO-OL trial; Table 2 ). In the absence of head-to-head comparison of the different ERAs it is obvious that hepatotoxicity is reduced in comparison with bosentan and that edema is less frequent than with bosentan and ambrisentan.
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